Equities Analysts Set Expectations for Immunome Q1 Earnings

Immunome, Inc. (NASDAQ:IMNM) – Research analysts at Lifesci Capital issued their Q1 2025 earnings per share (EPS) estimates for shares of Immunome in a research report issued on Tuesday, March 11th. Lifesci Capital analyst C. Zhu forecasts that the company will post earnings of ($0.61) per share for the quarter. Lifesci Capital currently has a “Outperform” rating and a $20.00 target price on the stock. The consensus estimate for Immunome’s current full-year earnings is ($2.21) per share. Lifesci Capital also issued estimates for Immunome’s Q2 2025 earnings at ($0.61) EPS, Q3 2025 earnings at ($0.67) EPS, Q4 2025 earnings at ($0.73) EPS, FY2025 earnings at ($2.62) EPS, Q1 2026 earnings at ($0.80) EPS, Q2 2026 earnings at ($0.81) EPS, Q3 2026 earnings at ($0.67) EPS, Q4 2026 earnings at ($0.62) EPS and FY2026 earnings at ($2.90) EPS.

Separately, Wedbush reissued an “outperform” rating and issued a $33.00 price objective on shares of Immunome in a research report on Monday, March 10th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $27.17.

Immunome Price Performance

IMNM opened at $8.77 on Thursday. The company has a market capitalization of $699.64 million, a price-to-earnings ratio of -1.08 and a beta of 1.93. The business’s 50-day moving average price is $9.98 and its two-hundred day moving average price is $11.80. Immunome has a 1 year low of $8.39 and a 1 year high of $26.70.

Hedge Funds Weigh In On Immunome

Institutional investors and hedge funds have recently made changes to their positions in the company. BNP Paribas Financial Markets acquired a new position in Immunome in the 4th quarter valued at $70,000. KLP Kapitalforvaltning AS bought a new stake in Immunome in the 4th quarter valued at about $75,000. AlphaQuest LLC increased its holdings in shares of Immunome by 786,700.0% during the fourth quarter. AlphaQuest LLC now owns 7,868 shares of the company’s stock worth $84,000 after purchasing an additional 7,867 shares during the period. Tower Research Capital LLC TRC increased its holdings in shares of Immunome by 482.0% during the fourth quarter. Tower Research Capital LLC TRC now owns 8,608 shares of the company’s stock worth $91,000 after purchasing an additional 7,129 shares during the period. Finally, Aquatic Capital Management LLC bought a new stake in shares of Immunome in the fourth quarter valued at approximately $95,000. Institutional investors and hedge funds own 44.58% of the company’s stock.

Insiders Place Their Bets

In related news, CEO Clay B. Siegall purchased 150,000 shares of the firm’s stock in a transaction that occurred on Friday, January 31st. The shares were acquired at an average price of $7.75 per share, for a total transaction of $1,162,500.00. Following the purchase, the chief executive officer now owns 669,636 shares in the company, valued at approximately $5,189,679. This represents a 28.87 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 8.60% of the company’s stock.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.